Medtronic PLC's stock experienced a significant pre-market surge of 5.55% on Wednesday, following the release of its fourth-quarter and full-year fiscal 2026 financial results.

The medical device maker reported quarterly revenue of $9.81 billion, surpassing the consensus estimate of $9.63 billion, driven by robust demand for its heart devices used in complex cardiac procedures. Adjusted earnings per share came in at $1.55, narrowly beating analysts' average estimate of $1.54. The company's cardiovascular segment, its largest business unit, saw sales jump 13.8% to $3.8 billion, powered by strong demand for its pulsed field ablation portfolio.

Investors looked past a slightly softer-than-expected fiscal 2027 outlook, focusing instead on the company's strongest annual revenue growth in a decade. Medtronic also announced a dividend increase and strategic investments in two intracardiac echocardiography catheter companies to expand its cardiac ablation portfolio, reinforcing positive sentiment around its growth trajectory.